Effect of smoking on thrombotic antiphospholipid syndrome: a 10-year prospective cohort study
- 20 September 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (7) , 1917-1922
Abstract
Cigarette smoking is an established risk factor for autoimmune diseases. However, whether smoking plays a clear role in thrombotic antiphospholipid syndrome (TAPS) has not been determined. We aimed to investigate the effects of smoking on clinical characteristics and prognosis of TAPS. This was a prospective cohort study from 2013 to 2022. During the study period, 297 patients were diagnosed with TAPS, including 82 smokers and 215 non-smokers. After propensity score matching, 57 smokers and 57 non-smokers matched by age and sex were analysed. Overall, smokers with TAPS had more cardiovascular risk factors (CVRFs) than non-smokers, including hypertension (36.59% vs. 14.42%, PP=0.029), dyslipidaemia (64.63% vs. 48.37%, P=0.012), and hyperhomocysteinaemia (62.20% vs. 36.28%, PP=0.013), especially myocardial infarction, visceral thrombosis, and peripheral vascular thrombosis. After matching, smokers showed balanced CVRFs with non-smokers at baseline, but retained a higher prevalence of arterial thrombosis (59.65% vs. 33.33%, P=0.005), mainly distributed in cerebral vascular, cardiovascular, and retinal vascular territories. During follow-up, smokers presented a tendency for more recurrent arterial thrombosis and less recurrent venous thrombosis. Smokers had significantly poorer outcomes for organ damage with higher DIAPS (median, 2.00 vs. 1.00, P=0.008), especially in the cardiovascular (26.32% vs. 3.51%, P=0.001), gastrointestinal (15.79% vs. 1.75%, P=0.016), and ophthalmologic (10.53% vs. 00.00%, P=0.027) systems. Smoking is related to increased arterial events and poor prognosis in TAPS patients. Patients with TAPS should be fully encouraged to avoid smoking.Keywords
Funding Information
- Chinese National Key Technology R&D Program, Ministry of Science and Technology (2021YFC2501300)
- Beijing Municipal Science & Technology Commission (Z201100005520022)
- CAMS innovation Fund for Medical Science (2021-I2M-1-005)
- National High Level Hospital Clinical Research Funding (2022-PUMCH-A-038, D-009)
This publication has 39 references indexed in Scilit:
- Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus ErythematosusAnnals of the Rheumatic Diseases, 2015
- Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patientsAnnals of the Rheumatic Diseases, 2015
- Smoking and Cardiovascular DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2014
- Adult Current Smoking: Differences in Definitions and Prevalence Estimates—NHIS and NSDUH, 2008Journal of Environmental and Public Health, 2012
- Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up studyAnnals of the Rheumatic Diseases, 2011
- Pathogenesis of antiphospholipid syndrome: understanding the antibodiesNature Reviews Rheumatology, 2011
- Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control studyThe Lancet Neurology, 2009
- Determinants of Risk for Venous and Arterial Thrombosis in Primary Antiphospholipid Syndrome and in Antiphospholipid Syndrome with Systemic Lupus ErythematosusThe Journal of Rheumatology, 2009
- Impact of hypertension and hyperhomocysteinemia on arterial thrombosis in primary antiphospholipid syndromeLupus, 2007
- The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritisRheumatology, 2006